{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-129018","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.310484+00:00","generated_at":"2026-06-07T07:12:58.490254+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cyclacel raises $1.29M through registered direct and private placements of stock and warrants","bullets":["Gross proceeds ~$1.29M from sale of 388,200 shares/pre-funded warrants at $3.315/share to institutional investors.","Issues unregistered warrants to purchase 388,200 shares at $3.19 each, exercisable for 7 years.","Insiders (CEO and CFO) purchase 7,956 shares and warrants on same terms in concurrent private placement.","Ladenburg Thalmann acts as placement agent; fees 8% of gross proceeds plus warrants.","Closing expected December 26, 2023; proceeds for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-129018","json":"https://secwatch.observer/filing/0001104659-23-129018.json","markdown":"https://secwatch.observer/filing/0001104659-23-129018.md","text":"https://secwatch.observer/filing/0001104659-23-129018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:12:58.490254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"149bfebb1fb2b43822c1bf3ee11757e9aff1100b","claim":"Bio Green Med Solution, Inc. entered into Securities Purchase Agreement with certain institutional investors (\"Purchasers\") valued at approximately $1.29 million (effective 2023-12-21).","evidence_excerpt":"On December 21, 2023, Cyclacel Pharmaceuticals, Inc. (the \"Company,\" \"we\" or \"us\") entered into a securities purchase agreement (\"Securities Purchase Agreement\") with certain institutional investors (\"Purchasers\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors (\"Purchasers\")"},{"label":"Value","value":"approximately $1.29 million"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"material_agreement"},{"claim_id":"988272cf61c1dbbde92e6de3bcd069f39aae1462","claim":"Bio Green Med Solution, Inc. entered into Securities Purchase Agreement with certain of our executive officers (effective 2023-12-21).","evidence_excerpt":"On December 21, 2023, in a separate concurrent insider private placement (the \"Insider Private Placement\"), we also entered into a Securities Purchase Agreement with certain of our executive officers (the \"Insider Securities Purchase Agreement\")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain of our executive officers"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"material_agreement"},{"claim_id":"e71c3dbb03a033c1406b9b2315c4ef0ba15f486d","claim":"Bio Green Med Solution, Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (the \"Placement Agent\") (effective 2023-12-21).","evidence_excerpt":"Ladenburg Thalmann & Co. Inc. (the \"Placement Agent\") acted as the exclusive placement agent for the Offerings, pursuant to a placement agency agreement (the \"Placement Agency Agreement\"), dated December 21, 2023, by and between the Company and the Placement Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc. (the \"Placement Agent\")"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}